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Abstract Thimerosal, a mercury-containing vaccine
preservative, is a suspected factor in the etiology of neu-
rodevelopmental disorders. We previously showed that its
administration to infant rats causes behavioral, neuro-
chemical and neuropathological abnormalities similar to
those present in autism. Here we examined, using micro-
dialysis, the effect of thimerosal on extracellular levels of
neuroactive amino acids in the rat prefrontal cortex (PFC).
Thimerosal administration (4 injections, i.m., 240 lg Hg/
kg on postnatal days 7, 9, 11, 15) induced lasting changes
in amino acid overﬂow: an increase of glutamate and
aspartate accompanied by a decrease of glycine and ala-
nine; measured 10–14 weeks after the injections. Four
injections of thimerosal at a dose of 12.5 lg Hg/kg did not
alter glutamate and aspartate concentrations at microdi-
alysis time (but based on thimerosal pharmacokinetics,
could have been effective soon after its injection). Appli-
cation of thimerosal to the PFC in perfusion ﬂuid evoked a
rapid increase of glutamate overﬂow. Coadministration of
the neurosteroid, dehydroepiandrosterone sulfate (DHEAS;
80 mg/kg; i.p.) prevented the thimerosal effect on gluta-
mate and aspartate; the steroid alone had no inﬂuence on
these amino acids. Coapplication of DHEAS with thimer-
osal in perfusion ﬂuid also blocked the acute action of
thimerosal on glutamate. In contrast, DHEAS alone
reduced overﬂow of glycine and alanine, somewhat
potentiating the thimerosal effect on these amino acids.
Since excessive accumulation of extracellular glutamate is
linked with excitotoxicity, our data imply that neonatal
exposure to thimerosal-containing vaccines might induce
excitotoxic brain injuries, leading to neurodevelopmental
disorders. DHEAS may partially protect against mercuri-
als-induced neurotoxicity.
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Introduction
Thimerosal, an organomercurial (THIM; sodium ethyl-
mercurithiosalicylate), has been used as a preservative in
liquid medicinal products, including pediatric vaccines, for
decades without being adequately tested for safety in
developing organisms. THIM, which contains approxi-
mately 49% mercury by weight and is composed of eth-
ylmercury (EtHg) and thiosalicylic acid, is metabolized in
the body to EtHg and further to inorganic forms of mercury
[1]. Previous studies reported that THIM administration to
rats leads to accumulation of mercury in the liver, kidneys
and the brain, where it may produce toxic effects [2–6].
Although THIM was withdrawn from use in primary
pediatric vaccines in most developed countries, it is still
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DOI 10.1007/s11064-011-0630-zpresent in vaccines intended for children and pregnant
women in developing countries [7–9].
Most guidelines for the medical use of THIM are based
on studies evaluating the toxicity of methylmercury
(MeHg), which has been studied more extensively. Ethyl-
mercury and MeHg appear to be similar with respect to
their initial distribution to the blood compartment, fecal
excretion and pharmacodynamics. Nevertheless, there are
some differences between them in tissue deposition and the
rate of transformation to inorganic mercury forms [3, 10,
11]. All mercurials, including THIM, are known to be
neurotoxic, especially during early brain development [12–
14]. The neurotoxic actions of postnatally administered
THIM were shown in mice and hamsters [15, 16]. Our
earlier studies documented that injections of THIM (i.m.)
at vaccine-level doses or higher to rat neonates decreases
viability of neurons and astrocytes in several brain regions,
disrupts opioid and dopamine systems and induces
behavioral deﬁcits, which resemble the symptoms of aut-
ism [4, 17–19]. Neurotoxic effects were also shown in
infant monkeys exposed to a THIM-containing vaccine
(TCV) [20, 21]. In vitro studies revealed that incubation of
neurons with THIM at nanomolar or micromolar concen-
trations leads to their death [22–25]. Neurotoxicity of
THIM is aggravated by its action depleting intracellular
glutathione—the peptide neuroprotective against metal
toxicity [13].
Some epidemiological studies reported that infant
exposure to TCVs is associated with neurodevelopmental
disorders, including autism [7, 26–29]. Despite the growing
number of studies documenting the neurotoxicity of THIM
in developing organisms, research in this area is still
fragmentary and controversial, demanding more wide-
ranging investigations to reach a consensus regarding its
postulated link with neurodevelopmental disorders.
Research is also needed to fully explain the complex
neurochemical mechanisms of THIM/mercurials-induced
neurotoxicity.
In contrast to THIM, MeHg has been studied more
comprehensively and is well-known as a neurotoxic sub-
stance [30, 31]. Based on similarities between EtHg and
MeHg with regard to chemistry, tissue distribution and
pharmacodynamics, the toxic effects of EtHg are believed
to be analogous to those of MeHg [2, 3]. One of the
hypotheses referring to the neurotoxicity of mercurials is
linked with excitotoxicity. By inhibiting glutamate uptake
in astrocytes and diminishing the activity of glutamine
synthetase, mercurials can induce extracellular accumula-
tion of glutamate, which can exert excitotoxic actions in
neurons [32–34].
Because MeHg has been shown to augment overﬂow of
glutamate in the brain [35], we were inquiring if THIM,
administered subchronically and acutely to rats, has a
similar effect. The present study aimed to: (1) evaluate the
long-term effects of THIM administration to neonatal rats
on extracellular levels of neuroactive amino acids (gluta-
mate, aspartate, glycine, GABA and alanine) in the PFC;
and (2) assess the acute effect on these amino acids when
THIM is administered directly to the brain. In addition (3)
we examined the potential modulatory effects of the
adrenal steroid hormone, dehydroepiandrosterone sulfate
(DHEAS), which is also a neurosteroid produced in the
brain [36, 37], where it modulates neurotransmission of
GABA and glutamate [38–40], inﬂuences the activity of
neuronal calcium channels [41], and acts as neuroprotec-
tive neurohormone [42–44]. Learning about neurochemical
mechanisms, which underlie the developmental neurotox-
icity of THIM is essential, because TCVs continue to be
used in many countries, potentially damaging the health of
children. Examining the interactions between THIM and a
neuroactive steroid—known to be altered in many neuro-
logical disorders—may aid the understanding of distinct
vulnerabilities of individuals to mercurial-induced neuro-
toxicity and contribute to unraveling the complex biolog-
ical processes involved in the pathogenesis of autism and
other neurodevelopmental disorders. In the long run, such
studies may assist the development of effective treatments
for these disorders.
Experimental Methods and Statistics
Animals, Chemicals, Experimental Design
Pregnant female rats and adult male rats of the Wistar
strain were supplied by the breeding house of the Medical
Research Centre, Polish Academy of Science, Warsaw,
Poland. The animals were kept in a room under standard
conditions (12–12 h light–dark cycle with light on at 7:00
a.m.), at constant temperature (21 ± 2C) and 60%
humidity. Laboratory chow and water were available
ad libitum. The experiments were carried out during the
light period. All tests were conducted according to the
ethical standards laid down in respective Polish and
European regulations (directive of 24 November 1986/609/
EEC). All experimental procedures were approved by the
local Committee for Animal Care and Use at Warsaw
Medical University. THIM and DHEAS were purchased
from Sigma–Aldrich, Poland.
The microdialysis experiments measuring extracellular
concentrations of amino acids in the PFC were conducted
on two cohorts of male rats. One cohort received four i.m.
THIM injections during the second postnatal week (neo-
natal THIM treatment model). Microdialysis was per-
formed when these animals were 12–16 week old; in this
group a delayed effect of THIM on extracellular brain
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123levels of amino acids was examined (N = 28). In a sepa-
rate cohort of adult male rats (12–16 week old) an effect of
THIM administered directly to the PFC was evaluated
(acute THIM treatment model), (N = 25).
Treatment of Neonates with Thim and Neurosteroids
Neonatal THIM treatment group: THIM dissolved in saline
was injected in a volume of 50 ll into the glutei maximi of
newborn rats on postnatal days (PND): 7, 9, 11, and 15 in
four equal-dose inoculations, based on the body weight.
This treatment schedule was originally used in mice by
Hornig and colleagues, imitating the US infant Vaccination
Scheme of the year 2001 [15], and was subsequently
employed by Laurente et al. [16] in the study on hamsters.
We have also used this THIM treatment scheme in our
previous studies in rats [4, 17–19]. The THIM doses per
injection were: 12.5 or 240 lg Hg/kg. The lower dose is in
the range of doses used in infant vaccinations in some
countries [4, 15]. The control group received saline injec-
tions. THIM-treated infant rats were allowed to grow with
their mothers and litters. They were weaned on PND 28.
Males were separated from females and allowed to reach
maturity.
Thirty min before THIM administration, some animals
received additional i.p. injections of DHEAS (dissolved in
50% water/saline in 50 ll) at a dose of 80 mg/kg, while
controls received saline-water injections. Rats from one
litter received the same drug treatment; there were two
litters per each type of treatment. The dosage of THIM was
chosen in reference to our previously conducted behavioral
and neuropathological studies [4, 17–19]. The dose of
DHEAS was selected to attain its likely micromolar con-
centrations in the brain, which have been shown to affect
neurotransmission [38–41].
Implantation of Dialysis Probes and Microdialysis
Procedure
Probes (4 mm membrane length, Eicom, Kyoto, Japan; cut
off 50 kDa, recovery for amino acids around 20%) and a
micro-syringe pump (BAS, USA) were used for the
microdialysis experiment. The 12–16 week old male rats,
which received neonatal injections of saline, THIM,
DHEAS, or THIM combined with DHEAS were anesthe-
tized with ketamine (100 mg/kg, i.p). The dialysis probe
was ﬁxed to the skull with anchor screws and dental acrylic
cement. The probe was stereotaxically implanted into the
PFC, taking bregma as a reference point (coordinates: ?3.2
AP, 0.6 ML, 4.0 DV) [45]. Probes were inserted at least
24 h before the experiment to allow for equilibration of the
extracellular environment around the probe tip.
Freely moving animals were kept in a microdialysis
round bottom bowl with access to water and food ad libi-
tum. Before implantation, the microdialysis probe was
ﬂushed with a Ringer’s solution (B. Braun Medical Inc.)
containing (mM): 147.2 NaCl, 4.0 KCl, 2.3 CaCl2. The
microdialysis sampling started after an initial 60 min sta-
bilization of Ringer ﬂuid perfusion at a ﬂow rate of 2 ll/
min. Eight successive samples were collected manually
over the 30 min periods.
A separate group of experimentally naı ¨ve 12–16 week
old male Wistar rats was used in the acute THIM admin-
istration study. The procedures of microdialysis, type of
probe and coordinates of implantation were the same as
described above. The microdialysis sampling started after
initial 60 min stabilization of Ringer ﬂuid perfusion at a
ﬂow rate 2 ll/min. First, three basal samples were col-
lected manually over the 30 min periods. Subsequently, the
solutions of THIM or HgCl2 (at 10 or 100 lM concentra-
tions) prepared in Ringer ﬂuid were infused during the
collection of the next three samples (90 min total). Finally,
the initial perfusion solution was restored for the last two
collected samples. In these (acute) experiments, we also
tested the effects of DHEAS (100 lM), coadministered
with THIM in the perfusion solution.
The collected microdialysis samples were immediately
frozen (-70C) at the end of each experimental session for
later amino acid analyses. When the microdialysis experi-
ment was terminated, the animals were sacriﬁced by an
overdose of i.p. pentobarbital injections, and then decapi-
tated. The brains were removed and sectioned to verify the
probe placement. The extracellular concentrations of
amino acids were determined in microdialysis samples by
HPLC with electrochemical detection.
HPLC Analysis
The electrochemical detection system composed of an
electrochemical detector with a ﬂow cell (Decade II Antec
Leyden, USA), Shimadzu CBM-20A controller system,
LC-20AD pump, and CTO-20AC oven (Shimadzu,
Germany) constituted the HPLC analytical system. The
analysis of amino acids was performed using a Gemini C18
5 lm (150 mm 9 4.6 mm) reversed phase column, pro-
tected by Security Guard cartridges (Phenomenex, USA).
A high-density glassy carbon electrode (Decade II Antec
Leyden, USA) was operated at ?0.85 V. Preparation of
the mobile phase and derivatizing agents were based on the
method of Rowley et al. [46] with modiﬁcations. The
mobile phase consisted of 26% methanol (Mallinckrodt
Baker, The Netherlands), 40 mM disodium phosphate and
0.8 mM EDTA with, adjusted to pH 3.9 with 0.2 M citric
acid (Sigma–Aldrich, Poland). It was ﬁltered through
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1230.45 lm ﬁlters (Millipore) and degassed for at least 15 min
prior to use.
Stock solutions of amino acid standards were prepared
in double deionized water and kept at 4C. Working
solutions were prepared daily by dilutions of stock solu-
tions. The OPA working solution was prepared as follows:
11 mg of OPA (Fluka, USA) was dissolved in 0.25 ml of
1MN a 2SO3, 0.25 ml absolute methanol and 0.45 ml of
0.1 M sodium tetraborate (Sigma–Aldrich, Poland) buffer
adjusted to pH 10.4 with 5 M sodium hydroxide. This OPA
stock reagent was stable for approximately 5 days and kept
tightly sealed in a brown bottle at room temperature. The
reaction of derivatization was performed at room temper-
ature. 20 ll of OPA working solution was added to 1 ml of
standard solution or dialysate, which was vortexed and
reacted for 15 min in a polyethylene vial.
A rheodyne injection valve with 20 ll sample loops was
used to manually inject the samples. The column was
maintained at a temperature of 30C. Compounds were
eluted isocratically with mobile phase delivered at a ﬂow
rate of 0.6 ml/min over a 30 min runtime after an injection.
Amino acids were identiﬁed by their characteristic reten-
tion time, comparing to retention times of sample peaks
with those of their respective standards. Standard curves
and stability data were generated using LC Solution soft-
ware. The concentration of amino acids was calculated
as lM.
Statistical Analysis
The Statistica 8 software package for Windows (StatSoft,
Tulsa, OK, USA) was used to analyze all experimental
data. An analysis of variance (ANOVA) with repeated
measure, followed by a post hoc Least Signiﬁcant Differ-
ences Fisher’s Test was employed. A probability value of
P\0.05 was considered signiﬁcant.
Results
Neonatal Treatment with THIM and DHEAS
The experiments measuring extracellular concentrations of
glutamate,aspartate,GABA,glycine,andalanineinthePFC
after neonatal administration of four doses of THIM with/or
without DHEAS were conducted on ﬁve groups of rats:
control/saline (N = 6), THIM 12.5 lg Hg/kg (N = 6),
THIM 240 lg Hg/kg (N = 6), DHEAS 80 mg/kg (N = 5),
THIM 240 lg Hg/kg ? DHEAS 80 mg/kg (N = 5).
Neonatal THIM injections provoked a long-lasting
increase in the extracellular levels of glutamate in the PFC
(Fig. 1). A two way ANOVA with repeated measures
revealed signiﬁcant differences between the treatment
groups: the effect of group F (4;23) = 5.9 (P\0.001), no
effect of sample F (7;161) = 0.32, (P = 0.94) and non
signiﬁcant group/sample interaction F (28;161) = 0.69,
(P = 0.87). The post hoc analysis (LSD) revealed that the
effect of a THIM dose of 240 lg Hg/kg was statistically
different from control (P\0.001), but the effect of a
12.5 lg Hg/kg dose was not signiﬁcant (P = 0.92) in this
measure. Administration of DHEAS alone to infant rats did
not cause signiﬁcant change in extracellular glutamate
levels in the PFC of adult animals (P = 0.71). However,
when this steroid was injected into rat neonates 30 min
before THIM, it prevented the stimulating effect of this
mercurial on glutamate overﬂow. The post hoc test
revealed a statistical difference between the groups of
THIM 240 and THIM 240 lg Hg/kg ? DHEAS
(P\0.001).
The results in Fig. 2 illustrate the inﬂuence of neonatal
administration of THIM and DHEAS, alone and in com-
bination, on overﬂow of aspartate in the PFC. THIM
treatment had a dose dependent effect on this amino acid.
The two way ANOVA with repetitions indicated signiﬁ-
cant group differences in aspartate concentration: the
effect of group [F (4;23) = 5.02, P = 0.004], sample
[F (7;161) = 6.7, P\0.001] and signiﬁcant group/sample
interaction [F (28;161) = 4.05, P\0.001]. The post hoc
analysis conﬁrmed a signiﬁcant effect for the THIM dose
of 240 lg Hg/kg (samples 4–7, P\0.001). Neonatal
administration of a THIM dose of 12.5 lg Hg/kg did not
Fig. 1 Effect of neonatal administration of THIM and DHEAS on the
concentration of extracellular glutamate in the PFC of adult rats.
Y axis: concentration of extracellular glutamate (lM); X axis:
dialysate sample numbers. Figure legend describes treatment groups.
The data are shown as means ± SEM from six animals per group.
Dialysates were collected at 30 min intervals in 8 time points. Four
THIM injections at a dose of 240 lg Hg/kg markedly increased the
extracellular level of glutamate. DHEAS (80 mg/kg) prevented the
effect of THIM, having per se no effect on glutamate concentration.
Statistical signiﬁcance compared with control **P\0.001; com-
pared with THIM 240 lg Hg/kg ? DHEAS
#P\0.001
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123cause an elevation of extracellular aspartate in adult rats
(P = 0.99). Coadministration of DHEAS 30 min before
THIM prevented its effect on aspartate overﬂow. Post hoc
analysis showed dissimilarity between the THIM 240 and
THIM 240 lg Hg/kg ? DHEAS groups, conﬁrming the
signiﬁcance of DHEAS action in preventing THIM-
induced aspartate overﬂow (P\0.001). The effects of
DHEAS alone and saline were not statistically different
(P = 0.68).
Neonatal THIM administration reduced the overﬂow of
glycine in the rat PFC, thus having an opposite effect on
this inhibitory amino acid than on the excitatory amino
acids—glutamate and aspartate (Fig. 3). ANOVA demon-
strated a signiﬁcant group differences in glycine levels:
effect of group [F (4;23) = 7.08, P\0.001], no effect of
sample [F (7;161) = 0.66, P = 0.7], and no signiﬁcant
group/sample interaction [F (28;161) = 0.75, P\0.8].
Post hoc analysis conﬁrmed a signiﬁcant reduction of
extracellular glycine concentration by a THIM dose
of 12.5 lg Hg/kg (samples 2–8), (P\0.001) and a dose of
240 lg Hg/kg (samples 4–5), (P\0.05). Administration
of DHEAS alone also decreased glycine levels
(P = 0.001). There was no statistical difference between
the effects of both THIM doses (P = 0.54) and DHEAS
(P = 0.46), but the effect of combined THIM 240 lg Hg/
kg ? DHEAS was signiﬁcantly greater than that of THIM
alone (P\0.05), indicating partly additive actions of both
agents in reducing glycine outﬂow.
THIM’s effect on extracellular alanine was also distinct
from its effect on glutamate or aspartate (Fig. 4). Two way
ANOVA with repeated measures revealed: an effect of
group [F (4;23) = 8.8, P = 0.001], no effect of sample
[F (7;161) = 1.65, P = 0.12] and an effect of group/sam-
ple interaction [F (28;161) = 1.78, P = 0.014]. Post hoc
analysis revealed a signiﬁcant reduction of extracellular
alanine in rats treated with a THIM dose of 240 lg Hg/kg
in comparisons with the saline group (samples 5–8,
P B 0.05), but not with a dose of 12.5 lg Hg/kg
(P = 0.73). DHEAS alone also signiﬁcantly reduced levels
of alanine with respect to saline (P\0.05). In rats injected
with a combination of THIM 240 lg Hg/kg and DHEAS,
the extracellular concentrations of alanine in the PFC were
not lower than in animals treated with DHEAS alone,
although they were signiﬁcantly lower than in animals
treated with saline (P\0.05).
The basal extracellular concentration of GABA in
microdialysis eluate (about 0.2 lM) was approximately 20
times lower than that of glutamate (4 lM). THIM admin-
istration appeared to somewhat elevate the GABA level,
while DHEAS slightly reduced it, but a two way ANOVA
with repeated measures disclosed only a statistical
tendency for THIM’s effects on GABA levels:
Fig. 2 Effect of neonatal administration of THIM and DHEAS on the
concentrations of extracellular aspartate in the PFC of adult rats.
Y axis: concentration of extracellular aspartate (lM); X axis: dialysate
sample number. Figure legend describes treatment groups. The data
are shown as means ± SEM from six animals per group. Dialysates
were collected at 30 min intervals in 8 time points. THIM injections
increased extracellular levels of aspartate; the effect was prevented by
coadministration of DHEAS (80 mg/kg). Values statistically different
from control *P B 0.004, and from THIM 240 lg Hg/kg ? DHEAS
#P\0.001
Fig. 3 The chronic effect of neonatal administration of THIM and
DHEAS on extracellular levels of glycine in PFC. Y axis: extracellular
concentration of glycine (lM); X axis: dialysate sample number.
Figure legend describes treatment groups. The data are shown as
means ± SEM from six animals per group. Dialysates were collected
at 30 min intervals in 8 time points. Neonatal THIM administration
decreased extracellular concentrations of glycine. DHEAS (80 mg/kg)
alone also reduced glycine levels and DHEAS administered with THIM
(240 lg Hg/kg) decreased it further. Statistical signiﬁcance com-
pared with control: *P\0.05, **P\0.001; compared with THIM
240 lg Hg/kg ? DHEAS
#P\0.05
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123[F (4;23) = 2.61, P = 0.06], no effect of sample
[F (7;161) = 1.71, P = 0.1] and no signiﬁcant group/
sample interaction [F (28;161) = 1.36, P\0.12] (data not
shown).
A summary of changes in the extracellular concentra-
tions of all tested amino acids in the PFC of rats exposed to
THIM during the neonatal period is shown in Table 1.
Acute perfusion with THIM
In order to examine direct effect of THIM and DHEAS on
overﬂow of amino acids in the PFC, a separate set of
experiments was performed with experimentally naı ¨ve
adult rats which received both substances acutely in the
perfusion ﬂuid. The animals were divided into ﬁve groups
based on the content of the perfusion ﬂuid: control/saline
(n = 5), THIM 10 lM( n= 5), THIM 100 lM( n= 5),
DHEAS 100 lM( n= 5), THIM ? DHEAS, 100 lM each
(n = 5). It is important to note that THIM concentrations in
the perfusion solutions are not equivalent to those attained
in the perfused tissues, where they are limited by factors
such as permeability and sorption by cellulose membranes
of the microdialysis probes [47]. Therefore, the THIM
concentrations which reach the tissue are probably signif-
icantly lower than those used in perfusion solutions.
Likewise, it is expected that only a fraction of the DHEAS
present in the perfusion ﬂuid reaches the brain tissues. We
have not measured the concentrations of both substances in
the perfused tissue. These experiments were intended pri-
marily to apprise qualitatively whether the effects of acute
THIM administration directly to the brain are similar (or
not) to those observed after its systemic administration to
infant rats. Perfusion of the PFC with THIM induced rapid
accumulation of extracellular glutamate in a dose-depen-
dent manner (Fig. 5). A two way ANOVA with repeated
measures (sample 9 group) revealed a signiﬁcant effect of
group [F (4;20) = 13.89, P\0.001], a signiﬁcant effect of
sample [F (6;120) = 12.69, P\0.001] and a signiﬁcant
sample/group interaction [F (24;120) = 11.91, P\0.001].
The perfusion with 100 lM THIM provoked a rapid raise
of extracellular glutamate concentration to 192 ± 18% of
the basal level in sample 4 and to 293 ± 68% in sample 6.
Post hoc analysis revealed a statistically signiﬁcant dif-
ference between basal and 100 lM THIM exposure for
samples 4–6 (P\0.001). Glutamate levels measured
during the perfusion with 100 lM THIM were also sig-
niﬁcantly different from those measured during THIM-
postexposure (P\0.001). An increase of glutamate over-
ﬂow during perfusion with 10 lM THIM, while noticeable,
did not reach statistical signiﬁcance (P\0.07).
Coadministration of 100 lM DHEAS with 100 lM
THIM during the perfusion period completely blocked the
action of THIM on glutamate, while per se this steroid was
without effect (Fig. 5). Post hoc analysis indicated signif-
icant difference between the group perfused with 100 lM
THIM and that perfused with 100 lM THIM ? DHEAS in
the exposure period (samples 4–6; P\0.001). There was
no statistical difference between THIM ? DHEAS and
control (P = 0.58). Post hoc analysis also did not show
dissimilarity between the groups DHEAS alone and
THIM ? DHEAS (P = 0.40), nor between DHEAS and
control groups (P = 0.77). In dialysate probes from the
PFC of rats perfused with THIM and DHEAS we also
measured overﬂow of aspartate, glycine and alanine. Nei-
ther acutely administered THIM, nor DHEAS alone or in
combination signiﬁcantly altered extracellular levels of
these amino acids.
Because THIM is metabolized in tissues to inorganic Hg
species, we compared its effect on glutamate to that of
Fig. 4 Effect of neonatal administration of THIM and DHEAS on the
concentrations of extracellular alanine in the PFC of adult rats. Y axis:
extracellular concentration of alanine (lM); X axis: dialysate sample
number. Figure legend describes treatment groups. The data are
shown as means ± SEM from six animals per group. Dialysates were
collected at 30 min intervals in 8 time points. THIM administration
(240 lg Hg/kg) reduced extracellular concentrations of alanine.
Coadministration of DHEAS decreased it further. Statistical signif-
icance compared with control *P\0.05; compared with THIM
240 lg Hg/kg ? DHEAS
#P\0.05
Table 1 Summary of changes in extracellular levels of neuroactive
amino acids in the PFC induced by administration of THIM, DHEAS











Glutamate Increase No change No change
Aspartate Increase No change No change
Glycine Decrease Decrease Decrease
Alanine Decrease Decrease Decrease
GABA NS NS NS
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123HgCl2. For this purpose we administered solutions of
10 lM HgCl2 (n = 4), 100 lM HgCl2 (n = 4), or saline
(n = 5) to the PFC in a manner identical to which THIM
was administered. Brain perfusion with HgCl2 also aug-
mented the overﬂow of glutamate (Fig. 6), but this mer-
curial appeared less potent than THIM, as at a 100 lM
concentration (in perfusate) it augmented the extracellular
glutamate level maximally by about 40% above the base-
line, while equimolar THIM elevated the glutamate level
nearly by 200%. The ANOVA with repeated measures
revealed a signiﬁcant effect of HgCl2 dose [F (2;10) =
5.25; (P\0.05)]. Post hoc analysis showed a statistical
difference between the basal and 100 lM HgCl2 exposures
(P = 0.001).
Discussion
Ours is the ﬁrst study—to the best of our knowledge—
documenting that administration of THIM to infant or adult
rats disrupts the balance between the excitatory and
inhibitory amino acids in the brain and that this effect is
prevented by the neurosteroid, DHEAS. Repeated i.m.
THIM injections to neonatal rats induced lasting elevation
of extracellular concentrations of glutamate and aspartate,
but decreased concentrations of glycine and alanine in the
PFC. Coadministration to these animals of DHEAS, which
per se did not alter glutamate and aspartate levels, pre-
vented THIM’s actions on these neurotransmitters. In
contrast, DHEAS reduced the overﬂow of glycine and
alanine, adding to THIM’s effects on these amino acids.
Acute, brief application of THIM in the perfusion ﬂuid
directly to the PFC in adult rats also induced a rapid
increase of glutamate overﬂow without altering the levels
of other amino acids. This effect was blocked by coad-
ministration of DHEAS as well.
Qualitatively, the actions of THIM on brain glutamate
were similar for the repeated neonatal exposure and acute
intracerebral administration in adult rats, but there were
important quantitative differences between them. In mature
animals, THIM administration to the PFC induced a brief
increase of glutamate overﬂow, which vanished after the
mercurial was washed out, whereas in rats which received
systemic THIM injections during the neonatal period, the
overﬂow of glutamate was long lasting. This may be due to
accumulation of mercury in the brains of neonatally THIM-
treated rats and due to the greater vulnerability to mercurial
neurotoxicity of immature animals. While discussing the
potential mechanisms of THIM’s actions on the brain neu-
roactive amino acids and their toxicological implications,
Fig. 5 Changes in extracellular levels of glutamate in the PFC during
acute perfusion with THIM and DHEAS. Y axis: change of
extracellular glutamate expressed as % of basal value; X axis:
dialysate sample number. Samples 1–3 represent basal values.
Samples 4–6 represent the period of exposure to 10 lM THIM,
100 lM TMIM, 100 lM DHEAS, or 100 lM THIM ? 100 lM
DHEAS (all compounds were dissolved in the Ringer perfusion ﬂuid).
Samples 7–8 present the period of post drug exposure—perfusion
with the Ringer solution only. Control group was perfused with
Ringer solution. Individual samples were collected manually over
periods of 30 min each; 8 samples per experimental animal were
collected. Each point represents the mean ± SEM from 5 animals per
experimental group; N = 25. The values plotted were not corrected
for recovery. Statistical signiﬁcance compared with control
*P\0.05, **P\0.001; compared with 100 lM THIM ?100 lM
DHEAS
##P\0.001
Fig. 6 Changes in extracellular glutamate in the PFC during
perfusion with HgCl2. Y axis: change of extracellular glutamate
expressed as % of basal value; X axis: dialysate sample number. First
3 samples constitute basal values. Samples 4–6 represent the exposure
period to 10 lM or 100 lM HgCl2 in the Ringer perfusion ﬂuid,
samples 7–8 represent the postexposure period. Control group was
perfused with Ringer ﬂuid only. Each point represents the mean ±
SEM from 4 to 5 animals; N = 13. The values plotted were not
corrected for recovery. Statistical signiﬁcance compared with basal
**P\0.001
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123it is important to take into account the effective concen-
trations and pharmacokinetics of this mercurial in the
brain. The microdialysis experiments with rats treated
with THIM during infancy were conducted 10 to 14 weeks
after THIM administration. At that time, in animals
which received four injections of THIM at doses of 12.5 lg
Hg/kg—equivalent to doses used in some pediatric vac-
cines [4]—no signiﬁcant changes in the overﬂow of glu-
tamate, aspartate, or alanine were observed; only a
reduction in glycine concentration was noted. In contrast,
four injections of THIM at a dose of 240 lg Hg/kg pro-
duced a profound, lasting rise in extracellular levels of
glutamate and aspartate, and a reduction of glycine and
alanine.
The pharmacokinetic studies in monkeys revealed that
Hg from systemic THIM administration accumulates in the
brain and remains there for months/years [3]. Our previous
study showed that in the rat brain the Hg level peaks on day
4 after neonatal (i.m.) THIM injection, reaching 13–14% of
the initial concentration (calculated per body weight), and
that half-life of THIM-Hg in the rat brain is approximately
8 days [4]. On day 30 after the injection, the amount of Hg
remaining in the rat brain was about 10% of that from day
4. Based on these data, we can calculate that at the time of
the microdialysis experiments (10–14 weeks after neonatal
THIM injections; present study) the probable brain Hg
concentrations in rats, which received four doses of
240 lg Hg/kg, were low nanomolar. Analogous Hg con-
centrations were likely to be present in the brains of rats
which received four doses of 12.5 lg THIM-Hg/kg during
the ﬁrst days/weeks after the injections, suggesting that the
lower THIM doses (used in the current study) could have
also increased levels of excitatory amino acids shortly after
THIM administration. This notion is supported by ﬁndings
of ischemic-like neuropathological changes in the brains of
rats which received this lower dose of THIM during the
neonatal period [18]. In acute treatment experiments, per-
fusion with a THIM dose of 100 lM induced a rapid raise
of glutamate overﬂow during the perfusion period—which
was gone after the mercurial wash out—while the perfu-
sion with 10 lM THIM did not have a signiﬁcant effect.
We have not measured Hg concentrations in the brain tis-
sue of THIM-perfused rats. As mentioned in the Results,
they are not the same as those present in the perfusion
solutions, but most likely much lower. It is not clear at
present, if persistent changes in the overﬂow of neuroactive
amino acids in the brains of animals exposed to THIM
during infancy resulted from a direct toxic effect of Hg on
amino acid release, uptake, or metabolism in neurons and
glia, or from developmental, neurotoxic modiﬁcations in
the brain architecture and function which altered neuro-
transmission. Nonetheless, the transient nature of the
changes observed after acute THIM administration in adult
rats and apparent lack of residual effects on excitatory
amino acids ten to fourteen weeks after neonatal exposure
to lower doses of THIM, suggest that its effect on these
neurotransmitters may be at least partially reversible after
Hg clearance from the brain.
The pharmacodynamic mechanisms of THIM-induced
changes in brain amino acids are probably complex, as
mercurials interact with many functional proteins and cell
structures, affecting various biological processes. They
may involve effects on amino acid metabolism, synaptic
and non synaptic release or uptake, altered function of
enzymes, and changes in gene expression. It is intriguing
that the neonatal THIM treatment caused prolonged alter-
ations in the levels of several amino acids in the PFC, but
the effect of brief THIM administration directly to the PFC
was speciﬁc mainly to changes in glutamate. In another
study, perfusion of medulla with a solution of Hg salt
(p-chloromercuriphenylsulphonic acid) was reported to
augment the overﬂow of several amino acids [48]. The
reason for this discrepancy remains to be clariﬁed, but it
could be due to differences in the chemical nature of the
mercurial used, the brain regions studied, or other meth-
odological distinctions. It is, however, not surprising to see
a divergence in the metabolism, release or uptake of amino
acids, which possess distinct neurochemical properties, are
secreted from different cell populations under various
physiological conditions, and undergo diverse metabolic
pathways. In fact, in astrocytes mercurials were found to be
less efﬁcacious in inhibiting uptake of an inhibitory than an
excitatory neurotransmitter [49].
In general, our ﬁndings are concordant with those of
Hornig et al. [15], reporting changes in the glutamate sys-
tem in neonatally THIM-exposed mice, and with data
regarding the effects of MeHg on brain glutamate [33–35,
49, 50], which point to its extracellular built-up. Such
mercurial-induced effects could ensue in part from inhibi-
tion of glutamate uptake by astrocytes [32, 33, 49], decline
of activity of glutamine synthetase [34], or other forms of
neurotransmitter release from intracellular pools [50].
Regardless of the mechanisms contributing to the described
alterations in neuroactive amino acids in the brains of
THIM-treated animals, they indicate a loss of balance
between excitatory and inhibitory neurotransmitters,
apparently leading to synergistic ampliﬁcation of neuronal
excitation. Glutamate—the main excitatory neurotransmit-
ter in the brain—mediates processes associated with neu-
ronal communication, regulation of brain development,
determination of cell survival and differentiation, formation
and elimination of synapses, among others. For these rea-
sons, maintenance of glutamate homeostasis in the CNS is
vital and its disturbance may have serious repercussions for
brain development and functioning. Due to the excitatory
properties of glutamate, large increase of its extracellular
Neurochem Res (2012) 37:436–447 443
123level may lead to excitotoxicity and neuronal damage,
contributing to neurodegenerative disorders [51–53].
Mercurial-mediated neurotoxicity involves many neu-
rochemical and cellular processes that engage glutamate,
such as oxidative stress, mitochondrial damage, rise of
intracellular Ca
2? and depletion of cellular glutathione [13,
54–58]. Mercurials have a high afﬁnity for thiols, hence
strongly react with the sulfhydryl groups of amino acids,
peptides and proteins. Mercury-protein interactions seem to
explain the inhibition of ion transporters, channels, recep-
tors, or glutamate transporters [49, 59–61]. Such mecha-
nisms certainly contribute to the neurotoxic actions of
THIM [13, 25, 62]. Due to its lipophilicity THIM easily
enters the brain, where it is converted to EtHg, and then to
other mercury species [1, 3, 11]. In infants its passage to
the brain is further facilitated by immaturity of the
blood–brain barrier [63]. Since developing brains are
hypersensitive to the neurotoxic actions of mercurials and
excitotoxic stimulation [64, 65], a persistent rise of the
extracellular glutamate level in brains of infant animals
may lead to neurodegeneration. Such effects have been, in
fact, documented in rats exposed in infancy to even low
doses of THIM [18].
The cellular processes mediating THIM-induced decline
in overﬂow of glycine and alanine are also unknown at
present. In the brain stem and spinal cord neurons, glycine
transporters are inhibited by mercurials [66]. If they
function similarly in the PFC, one would expect to observe
an increase of glycine overﬂow in this structure, but this
was not the case in our experiments. However, ‘‘orphan
transporters’’ selective for glycine, proline, alanine and
leucine have been identiﬁed in synaptic vesicles of gluta-
matergic and GABAergic cortical neurons [67]. They may
be regulated by different mechanisms and respond
diversely to mercurials than the glycine transporters in
spinal cord neurons.
The neurotoxicological consequences of THIM-medi-
ated changes in the overﬂow of neuroactive amino acids
are predictable. A rise of the synaptic concentrations of
glutamate and aspartate and a decline of glycine and ala-
nine may shift the balance in favor of neuronal stimulation,
leading to excitotoxic neuronal injuries. Augmented
activity of excitatory amino acids may also distort critical
developmental processes in the brain, including survival
and differentiation of neurons, apoptosis and formation of
functional synapses, thus contributing to neurodevelop-
mental disorders. The roles of glycine and alanine in these
phenomena may be ambiguous however. In the cortex of
adult mammals these amino acids function mainly as
inhibitory transmitters [68, 69], but in the neonate cortex
glycine is excitatory, as it depolarizes neurons via strych-
nine-sensitive receptors [70]. Glycine also acts as coagonist
of NMDA receptors, augmenting their excitatory function
[71]. In this context, the THIM-induced decrease of glycine
overﬂow may be viewed as potentially protecting neurons
from excessive stimulation, for it would diminish excita-
tion via strychnine-sensitive receptors in the neonate cor-
tex, and excitation via the NMDA receptors in adult
animals.
The important novel ﬁnding of this study is that DHEAS
prevents some of the THIM-induced changes in overﬂow
of cortical amino acids. In the neonatal treatment model,
pups received DHEAS injections 30 min before THIM.
Microdialysis experiments showed that treatment with this
steroid blocked the THIM effect on glutamate and aspar-
tate. A similar effect was noted when DHEAS was coad-
ministered with THIM in the perfusion ﬂuid to the brain.
DHEAS action on inhibitory amino acids was unlike that
on glutamate, as this steroid alone diminished overﬂow of
glycine and alanine and further enhanced the inhibitory
effect of THIM on their release. This is additional evidence
of a divergence of mechanisms regulating the transport of
excitatory and inhibitory amino acids in the PFC.
DHEAS, a sulfated derivative of dehydroepiandroster-
one, is the most abundant steroid hormone in blood of adult
humans and a neurosteroid synthesized in the brain. DHEA
and DHEAS, which are interconvertible in the body, have
multiple functions in the CNS. DHEAS, in addition to
acting as a regulator of gene expression, interacts with the
GABAA, NMDA, and glycine receptors, thus modulating
neurotransmission, inﬂuencing brain development and
neuronal plasticity among other processes [37–41, 72].
DHEAS has also shown neuroprotective features in dif-
ferent models of brain injury [43, 73], and may guard
neurons from the neurotoxic actions of excitatory amino
acids [44, 74]. Our ﬁndings imply that it may as well
protect against some aspects of mercurial neurotoxicity. It
may bind to mercurials in a manner similar to that of spi-
ronolactone and other sulfur-containing steroids [75, 76],
making them biologically less active. Alternatively, since
some steroids (testosterone and cholesterol) augment the
activity of glutamate/aspartate transporters in epithelial
cells and primary cortical cultures [77, 78], DHEAS may
act in a comparable way in neurons or glia, counteracting
the effect of mercurials on these neurotransmitters.
In summary, the present study documents that exposure
of infant rats to THIM perturbs the balance between
excitatory and inhibitory amino acids in the brain, shifting
it toward excessive neuroexcitation. DHEAS prevents
some of these effects. Despite of intrinsic limitations,
present ﬁndings have important clinical implications, as
they provide a plausible mechanism, whereby THIM exerts
neurotoxic effects in the brain. It is likely that this mer-
curial—still present in pediatric vaccines in many coun-
tries—causes a similar disturbance of excitatory and
inhibitory neurotransmitters in the brains of human infants,
444 Neurochem Res (2012) 37:436–447
123leading to neurotoxicity, encephalopaties, and in conse-
quence to neurodevelopmental disorders, including autism
[7, 8, 20, 21, 26–29]. TCVs may lead to neurodegenerative
diseases in adults as well. Another potential clinical sig-
niﬁcance of this study pertains to the protective effect of
DHEAS. Augmented levels of androgens have been
reported in the blood of autistic children [79] and we found
elevated concentrations of many steroids, including
DHEAS, in the saliva of such children (manuscript in
preparation). While anomalous steroid levels certainly may
disturb brain development, the present data suggest that
they may also protect against some aspects of mercurial-
mediated neurotoxicity. On the whole, the current study
provides further empirical evidence that exposure to THIM
leads to neurotoxic changes in the developing brain,
arguing for urgent and permanent removal of this pre-
servative from all vaccines for children (and adults) since
effective, less toxic and less costly alternatives are avail-
able. The stubborn insistence of some vaccine manufac-
turers and health agencies on continuation of use of this
proven neurotoxin in vaccines is testimony of their disre-
gard for both the health of young generations and for the
environment.
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